The clinical development of paclitaxel: A successful collaboration of academia, industry and the National Cancer Institute

Stem Cells

Volumn 14, Issue 1, 1996, Pages 25-28

  Donehower, R C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cisplatin; Cytotoxicity; Paclitaxel; Taxol ; Tubulin

Indexed keywords

CISPLATIN; DOXORUBICIN; PACLITAXEL;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG DEVELOPMENT; DRUG IDENTIFICATION; DRUG INDUSTRY; DRUG ISOLATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; MYALGIA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; REVIEW;

EID: 0030052877     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.140025     Document Type: Review

References (2)

1. 1 Rowinsky EK, Donehower RC. Drug Therapy: Paclitaxel (Taxol ®). N Engl J Med. 1995 ; 332: 1004–1014.
2. 2 Proceedings of the Second National Cancer Institute Workshop on Taxol ® and Taxus. Monographs of the Journal of National Cancer Institute. 1993 ; 15: 1–199.